Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans trimmed its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 45.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 942,829 shares of the biopharmaceutical company’s stock after selling 772,015 shares during the quarter. Thrivent Financial for Lutherans owned 0.74% of Halozyme Therapeutics worth $49,367,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of HALO. TD Asset Management Inc increased its holdings in shares of Halozyme Therapeutics by 28.1% in the 1st quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company’s stock valued at $103,379,000 after purchasing an additional 557,350 shares during the period. Congress Asset Management Co. MA increased its holdings in shares of Halozyme Therapeutics by 16.2% in the 1st quarter. Congress Asset Management Co. MA now owns 407,867 shares of the biopharmaceutical company’s stock valued at $16,592,000 after purchasing an additional 56,791 shares during the period. Boston Trust Walden Corp acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at about $23,211,000. Los Angeles Capital Management LLC increased its holdings in shares of Halozyme Therapeutics by 17.2% in the 1st quarter. Los Angeles Capital Management LLC now owns 121,000 shares of the biopharmaceutical company’s stock valued at $4,922,000 after purchasing an additional 17,716 shares during the period. Finally, Norden Group LLC increased its holdings in shares of Halozyme Therapeutics by 1,817.3% in the 1st quarter. Norden Group LLC now owns 167,284 shares of the biopharmaceutical company’s stock valued at $6,805,000 after purchasing an additional 158,559 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Halozyme Therapeutics

In other news, CFO Nicole Labrosse sold 5,000 shares of the firm’s stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $53.93, for a total value of $269,650.00. Following the sale, the chief financial officer now owns 15,480 shares in the company, valued at $834,836.40. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $59.20, for a total transaction of $592,000.00. Following the sale, the chief executive officer now owns 676,744 shares in the company, valued at $40,063,244.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Nicole Labrosse sold 5,000 shares of Halozyme Therapeutics stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $53.93, for a total transaction of $269,650.00. Following the sale, the chief financial officer now owns 15,480 shares in the company, valued at approximately $834,836.40. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 84,881 shares of company stock worth $4,888,184. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Down 0.4 %

NASDAQ:HALO opened at $59.24 on Monday. Halozyme Therapeutics, Inc. has a 12 month low of $32.83 and a 12 month high of $65.53. The firm has a market cap of $7.54 billion, a price-to-earnings ratio of 24.48, a P/E/G ratio of 0.57 and a beta of 1.28. The company has a quick ratio of 6.21, a current ratio of 7.41 and a debt-to-equity ratio of 5.19. The company’s 50 day moving average is $58.40 and its 200-day moving average is $49.25.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.18. The business had revenue of $231.40 million for the quarter, compared to the consensus estimate of $204.94 million. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. Halozyme Therapeutics’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter last year, the company posted $0.68 earnings per share. Equities analysts anticipate that Halozyme Therapeutics, Inc. will post 3.7 EPS for the current year.

Analyst Upgrades and Downgrades

HALO has been the topic of a number of research reports. Benchmark reiterated a “buy” rating and issued a $60.00 target price on shares of Halozyme Therapeutics in a report on Thursday, August 8th. Piper Sandler downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price objective for the stock from $48.00 to $51.00 in a report on Friday, June 7th. The Goldman Sachs Group increased their price objective on Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a report on Monday, July 22nd. TD Cowen increased their price objective on Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, Morgan Stanley increased their price objective on Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.00.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.